The first human trial of the flu vaccine has been successful

 New York: Scientists have succeeded in the first phase of the "universal flu vaccine" medical trials (Phase One clinical trials) to prevent seasonal colds, after which they are preparing to launch the second phase of medical trials.

It should be noted that a special type of protein called "hemagglutinin" (HA) is found on the surface of the flu virus ie "flu virus". Any flu vaccine enables our natural defense system to identify and eliminate the flu virus based on that protein. 

However, the upper part of the "HA" protein, which current vaccines use as an "identification point", has the potential to change very quickly. 

That is why every year a new vaccine has to be developed to prevent the spread of seasonal flu because last year's vaccine has failed. 

A few years ago, experts discovered that another part of the same "HA" protein, the "HA Stack", is similar to almost all types of flu viruses, which are very similar. Less variable and can be used to identify any strain of the flu virus. 

Scientists want to develop a flu vaccine that not only protects against most types of colds but also lasts for years. Although no such vaccine has yet been developed, experts have dubbed it the "universal flu vaccine."

Although many universal flu vaccines are currently in various stages of development, at least three of them have reached a critical stage, such as the Phase One clinical trial. 

However, the vaccine, developed in collaboration with various US research institutes led by Mount Sinai Hospital, is the first universal flu vaccine to be successful at this stage. 66 volunteers participated in Phase One clinical trials of this vaccine which were divided into 5 groups to test the effectiveness and efficiency of this vaccine.

Details of these clinical trials, published in the latest issue of the research journal Nature Medicine, show that almost all of the vaccine volunteers had antibodies against the flu virus 18 months later to their natural defense system. addresses flu activity. 

If this vaccine proves to be just as effective in the second and then third phases of human clinical trials, it is to be hoped that in the next five to six years we will have a flu vaccine that is likely to be effective for many years. No new flu vaccine will be needed each year.